Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlo Pozzilli

Showing results (191-200 of 247) with videos related to

Pageof 25
Sort By:
Multiple Sclerosis and Related Disorders|July 23, 2025
Ponesimod as add-on treatment in patients with active relapsing multiple sclerosis under dimethyl fumarate (POINT): A phase 3, randomized, placebo-controlled clinical trialLudwig Kappos, Michel Burcklen, Daniele D'Ambrosio, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 2, 2019
Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studiesBart Van Wijmeersch, Barry A Singer, Aaron Boster, et al.
Journal of the Neurological Sciences|January 22, 2026
Directions for advancing prognostic assessments in multiple sclerosis: Qualitative Insights from MS specialist InterviewsSofie Aerts, Lotte Geys, Deborah Severijns, et al.
Multiple Sclerosis and Related Disorders|January 21, 2021
Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 yearsAnn D Bass, Rafael Arroyo, Aaron L Boster, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 16, 2015
No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study)Roberta Lanzillo, Mario Quarantelli, Carlo Pozzilli, et al.
Journal of Neurology|November 24, 2016
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosisLuca Prosperini, Francesco Saccà, Cinzia Cordioli, et al.
Neurology and Therapy|June 24, 2021
Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS StudiesSamuel F Hunter, Rany A Aburashed, Raed Alroughani, et al.
Plos One|June 28, 2016
The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective StudyEmanuele D'Amico, Carmela Leone, Giusi Graziano, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 5, 2022
Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational studyDamiano Baroncini, Angelo Ghezzi, Clara Guaschino, et al.
Neurology and Therapy|June 2, 2022
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up StudyMaria Petracca, Serena Ruggieri, Elena Barbuti, et al.
Pageof 25

Showing results (191-200 of 247) with videos related to

Sort By:
Pageof 25
Multiple Sclerosis and Related Disorders|July 23, 2025
Ponesimod as add-on treatment in patients with active relapsing multiple sclerosis under dimethyl fumarate (POINT): A phase 3, randomized, placebo-controlled clinical trialLudwig Kappos, Michel Burcklen, Daniele D'Ambrosio, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 2, 2019
Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studiesBart Van Wijmeersch, Barry A Singer, Aaron Boster, et al.
Journal of the Neurological Sciences|January 22, 2026
Directions for advancing prognostic assessments in multiple sclerosis: Qualitative Insights from MS specialist InterviewsSofie Aerts, Lotte Geys, Deborah Severijns, et al.
Multiple Sclerosis and Related Disorders|January 21, 2021
Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 yearsAnn D Bass, Rafael Arroyo, Aaron L Boster, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 16, 2015
No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study)Roberta Lanzillo, Mario Quarantelli, Carlo Pozzilli, et al.
Journal of Neurology|November 24, 2016
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosisLuca Prosperini, Francesco Saccà, Cinzia Cordioli, et al.
Neurology and Therapy|June 24, 2021
Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS StudiesSamuel F Hunter, Rany A Aburashed, Raed Alroughani, et al.
Plos One|June 28, 2016
The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective StudyEmanuele D'Amico, Carmela Leone, Giusi Graziano, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 5, 2022
Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational studyDamiano Baroncini, Angelo Ghezzi, Clara Guaschino, et al.
Neurology and Therapy|June 2, 2022
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up StudyMaria Petracca, Serena Ruggieri, Elena Barbuti, et al.
Pageof 25